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ABSTRACT
Introduction Knee osteoarthritis is a chronic degenerative 
disease associated with significant chronic pain, disability 
and impaired quality of life and is the most common form 
of osteoarthritis. There is no cure for knee osteoarthritis, 
and the main therapeutic goals are pain management and 
improving quality of life. The objective of this study is to 
evaluate the relative efficacy and acceptability of available 
interventions using network meta- analysis (NMA) to 
provide a comprehensive evidence base to inform future 
treatment guidelines.
Methods and analysis A comprehensive literature 
search of major electronic databases (MEDLINE, EMBASE, 
Cochrane Central Register of Controlled Trials) and clinical 
trial registries will identify randomised control trials (RCTs) 
of interventions listed in NICE guidelines for the treatment 
of knee osteoarthritis in adults. We will perform an NMA 
to estimate relative intervention effects across the whole 
treatment network. If any studies use multicomponent 
intervention packages, we will employ a component 
NMA model to estimate the contribution of individual 
components. The quality of evidence will be assessed 
using the Confidence in Network Meta- Analysis approach, 
which is based on the traditional GRADE framework 
adapted for NMA. Risk of bias (RoB) will be assessed using 
the revised Cochrane RoB 2.0 tool for RCTs.
Ethics and dissemination This study does not require 
ethical approval. Findings will be submitted to a peer- 
reviewed journal.
PROSPERO registration number CRD42020184192.
BACKGROUND
Osteoarthritis (OA) is a chronic degenerative 
musculoskeletal disorder of the joints, which 
most commonly affects the knee, hip and 
hand.1 OA is characterised by microscopic 
and macroscopic anatomical changes of 
the joint with a complex pathophysiological 
change of articular cartilage and subchon-
dral bone.2 This complex pathophysiology 
leads to cartilage degradation, bone remod-
elling, osteophyte formation and synovial 
inflammation, causing pain, disability and 
loss of normal biomechanical joint function.3 
OA resulting from ‘wear and tear’ is by far 
the most common and typically develops at 
around 55–60 years; although secondary OA 
resulting from injury, congenital abnormality 
or inflammation can also occur.1
OA is the most common form of arthritis 
and affects more than 300 million people 
worldwide.3 Since OA is associated with major 
structural changes of the joints leading to 
pain and functional disability, its epidemio-
logical and economic burden on healthcare 
providers and society are substantial.4 OA was 
estimated to be the fourth- leading cause of 
disability by the year 2020.5 In the UK alone, 
it is estimated that around 34% of people 
aged 45 years and older, approximately 8.75 
million people, have sought treatment for 
OA.6 The economic burden can be direct 
(eg, treatments) or indirect (eg, working days 
lost). A study in 2013 estimated that the nega-
tive economic impact of OA on UK economy 
Strengths and limitations of this study
 ► Network meta- analysis (NMA) will estimate the rela-
tive effects of two treatments even when no primary 
studies have directly compared them.
 ► Component NMA will assess the relative contri-
butions of individual components in a treatment 
package.
 ► Confidence in Network Meta- Analysis methodolo-
gy will providence confidence ratings of evidence 
quality.
 ► Individual treatment component effects may not be 
estimable if there are insufficient combined inter-
vention studies.
 ► Treatments that violate the consistency assumption 
cannot be reliably assessed with NMA.
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was the equivalent of 1% Gross National Product.7 The 
most common form of OA affects the knee joint and 
accounts for almost 83% of OA burden.8 9 Furthermore, 
because of the knee joint’s anatomical location its impact 
on disability is substantial.10
Currently, there is no cure for OA. As pain is the most 
common symptom associated with OA, with more than 
66% of patients with OA in constant pain,11 interven-
tions are primarily focused on pain management using 
a range of non- pharmacological and pharmacological 
approaches.3 While there is an abundance of research 
evaluating the effectiveness of different interventions 
compared with placebo, the question of which treatment 
is optimal is inhibited by a lack of data on the relative 
efficacies of competing interventions. Similarly, a better 
understanding of the relative adverse effects of different 
treatments is needed, with the risk- to- benefit ratio a crit-
ical aspect of decision making. This is particularly true 
in the geriatric population where OA is most prevalent 
and for whom treatment selection is often determined 
by adverse events, patient compliance and polypharmacy 
considerations.12
Network meta- analysis (NMA) provides a powerful 
means of providing relative estimates of the effects of 
different interventions for a particular indication.13 NMA 
allows the synthesis of data from both head- to- head trials 
and placebo- controlled trials and can provide estimates 
of relative treatment effects among any two treatments in 
the network, even in the absence of any existing head- 
to- head trials. Furthermore, component NMA (CNMA) 
allows the estimation of the effects of individual compo-
nents of combined treatments and can be especially 
useful for indications commonly treated by intervention 
packages.14
The objective of this NMA is to assess the relative effec-
tiveness and acceptability of treatments for the manage-
ment of pain from knee OA. As surgical interventions are 
generally used as a last resort, we will focus on non- surgical 
treatments and examine interventions listed in the NICE 
2014 guidelines CG17715 or the NICE 2017 surveillance 
guideline update report.16 The project is called Relative 
Effectiveness of Interventions for Knee Osteoarthritis.
METHODS
The protocol conforms to Preferred Reporting Items 
for Systematic review and Meta- Analysis Protocols (PRIS-
MA- P) guidelines17 for the reporting of systematic review 
and meta- analysis protocols (see online supplemental 
file 1) and also incorporates additional considerations 
specific to NMA (online supplemental file 2). Eligibility 
criteria were developed using the Population, Interven-
tion, Comparison, Outcome, Study framework, which 
are summarised in table 1 and described in detail in 
the sections below. The planned start date for the initial 
searches is September 2021 and we aim to complete the 
study by September 2022.
Population
We will include studies of adults (≥18 years) with knee OA 
based on a clinical or radiographic diagnosis. Where a 
mixed arthritis sample has been used, we will only include 
the study if (A) data for participants with knee OA can be 
extracted separately, or (B) at least 75% of the sample has 
knee OA.
Interventions
We will include interventions for pain management in 
knee OA with any of the treatment components listed 
below. These interventions were chosen for inclusion as 
they are either recommended in NICE (2014) guidelines 
(CG177) for the management of knee OA pain or listed 
in the NICE (2017) interim review as potential candi-
dates for inclusion in future guidelines. The rationale for 
focusing on internationally recognised clinical guidelines 
is that these interventions more likely to be prescribed or 
recommended for patients.
Pharmacological: Paracetamol, topical Non- Steroidal 
Anti- Inflammatory Drugs (NSAIDs), NSAIDs (non- 
selective) with or without a proton pump inhibitor, 
COX- 2 inhibitors, opioids, topical capsaicin, duloxe-
tine, intra- articular hyaluronan injections, intra- articular 
corticosteroid injection. Non- pharmacological: aerobic 
exercise, local muscle strengthening, education, local 
thermotherapy, TENS (transcutaneous electrical nerve 
stimulation), electromagnetic field therapy, ultrasound.
Table 1 Summary of PICOS eligibility criteria (detailed 
descriptions in manuscript text)
Inclusion criteria Exclusion criteria
Population Adults (≥18 years) with 
knee osteoarthritis 
based on a clinical or 
radiographic diagnosis
  
Intervention Non- surgical primary 
care interventions for 
pain management 
of knee OA based 
on National Institute 







Comparison Another active 
intervention or control 
(placebo/sham, 
treatment as usual, no 
treatment)
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Medications may be fixed or flexibly dosed. For medi-
cations approved for pain, we will only include study 
arms where dosages are within the licensed range. 
Where a drug is used off- label, we will include all trials 
but perform sensitivity analysis removing study arms 
using dosages outside the approved range for that 
drug’s indication. If different dosages have been used 
across multiple arms within a study, we will combine data 
and treat as a single node; unless multiple studies are 
available with similar dosing levels for that medication, 
in which case we will consider treating these as separate 
nodes.
Comparator(s)
A different eligible individual treatment or a control 




Self- reported pain assessed with the following measures in 
order of prioritisation as recommended by Juhl et al18: (1) 
the Western Ontario and McMaster Universities Arthritis 
Index (WOMAC) pain subscale, (2) a Visual Analogue 
Scale (VAS)/Numerical Rating Scale (NRS) pain rating 
measure and (3) any other acceptable instrument for 
pain listed in Osteoarthritis Research Society Interna-
tional (OARSI) guidelines for the non- surgical manage-
ment of OA.19
Assessment will be at the following distinct time periods 
following allocation to treatment: immediate (up to 2 
weeks), short- term (closest to 3 months), medium- term 
(closest to 6 months) and long- term follow- up (closest to 
12 months). If these divisions fail to sensitively reflect the 
pattern of assessment timings used across studies, we may 
reclassify these windows prior to analysis to reflect trial 
practices.
As many pharmacological interventions are often 
trialled for immediate- term and short- term outcomes, 
and non- pharmacological treatment (eg, exercise) trials 
may more frequently include long- term outcomes, sepa-
rate analyses in each time window ensures that treatments 
are compared in time windows appropriate for how those 
interventions are used.20
When pain ratings have been collected at multiple time 
points within a time window, we will use the time point 
closest to the median value across studies for the imme-
diate and short- term windows and the longest follow- up 
for the long- term follow- up window. If data were collected 
across multiple time points but only reported for a subset 
of these, we will make every possible attempt to retrieve 
all data to reduce the possibility of exaggerated treatment 
effects from selective reporting.21 If we are unable to 
retrieve the preferred data, we will use outcomes at the 
next closest time point but conduct sensitivity analysis 
excluding these studies.
Secondary outcomes
1. Acceptability—the proportion of patients in each 
group who withdraw before the end of the treatment 
for (A) any reason and (B) due to adverse effects.
2. Physical function—any valid patient reported outcome 
of physical functioning, with prioritisation of the WO-
MAC function subscale.
3. Stiffness—any valid patient reported outcome of stiff-
ness prioritising the WOMAC stiffness subscale.
Study designs
Only randomised controlled trials (RCTs) comparing an 
active intervention with another eligible intervention or 
control will be included. Randomisation can be at the 
individual or group level. SEs from cluster RCTs will be 
adjusted to account for design effects using a standard 
formula.22 Both parallel group and crossover designs 
will be included, although for cross- over designs we will 
extract data from the first trial period only to eliminate 
the possibility of carryover effects.
Measures of effect size
For continuous scores (pain, physical function, stiffness), 
we will compute the mean difference (MD) as the effect 
size, based on differences in post- treatment scores but 
using group differences in change scores if these are 
unavailable (which for randomised designs should give 
the same expected effect sizes as postscore differences, 
but often with larger variance).
As the WOMAC scale is available with three different 
response formats (0–4, 0–10 and 0–100)23 we will normalise 
all WOMAC scores to the metric of the most commonly 
used format.24 If a non- WOMAC measure has been used, 
we will attempt to normalise scores to the WOMAC metric 
using any conversion algorithm that may exist. If a study 
assesses pain both under load (eg, while walking) and at 
rest we will take the average of these measures (consistent 
with the WOMAC scoring), otherwise we will use which-
ever of the two is reported and examine the impact of 
this decision in sensitivity analysis. If a substantial number 
of scale conversions are necessary, we will use the stan-
dardised MDs as the effect size.
For the binary outcomes of acceptability, we will 
compute the OR comparing the odds of discontinuation 
in one intervention with the odds of discontinuation in 
another intervention/control arm.
Information sources
The following bibliographic sources will be searched for 
studies indexed from database inception to the date of the 
search: MEDLINE, MEDLINE In- Process, EMBASE and 
the Cochrane Central Register of Controlled Trials. We 
will also search for unpublished and ongoing trials using 
the WHO International Clinical Trials Registry Platform 
and  ClinicalTrials. gov. It is important to include unpub-
lished data, since the well- known bias towards publication 
of significant findings can, when relying on published 
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literature alone, lead to an overestimation of treatment 
effects and an underestimation of adverse effects.25
Where complete data for a relevant outcome are not 
available from a report of an eligible trial, we will contact 
authors to request data. In addition, we will conduct a 
manual search of relevant reviews and reference lists of 
eligible studies.
Search strategy
A broad search strategy will be used to identify eligible 
trials using controlled vocabulary terms and free- text 
keywords of titles and abstracts relating to randomised 
trials, OA and pain. For identifying randomised trials, 
we will use RCT filters provided by the Cochrane group 
for MEDLINE and by Wong et al26 for Embase. No 
publication date or language restrictions will be imple-
mented, although studies for which a translation cannot 
be obtained will be listed as potentially eligible but not 
considered for full review. Searches will be rerun just 
before submission of the review and updated to account 
for any additional data. The search strategy for Medline 
(OVID) is provided in online supplemental file 3.
Study selection
Titles and abstracts of each record returned by initial 
searches will be independently screened by BA and one 
other member of the review team, who will exclude 
studies not meeting eligibility criteria. BA and one other 
reviewer will then independently screen the full text of 
remaining articles, retaining only eligible studies for 
inclusion in the NMA. Disagreements at any stage will be 
resolved through discussion or with a third member of 
the review team if necessary.
Statistical analysis plan
Data extraction
One reviewer (BA) will perform data extraction and 
coding, with extracted data checked for accuracy by an 
experienced data analyst from the review team. We will 
use a standardised coding form based on our previous 
studies accompanied by an explanatory codebook. Infor-
mation extracted will include: study characteristics (such 
as trial design, source of financial support, trial size, study 
location), participant and disease characteristics (such as 
mean age, male/female ratio, disease duration, disease 
severity and baseline pain severity), intervention and 
control details, outcome data (including timing of assess-
ments and any information provided on missing data).
When available study data do not allow computation 
of effect sizes using standard formula we will: (A) extract 
inferential statistics (eg, F, p, t) that allow effect sizes to 
be computed,27 (B) contact study authors for data and 
(C) for missing SDs, used the pooled SD from other 
similar studies.28 In the event of the same data published 
in multiple sources, we will extract data from the source 
which reports data with the most clarity. In the case of 
both published and unpublished data being available, 
we will prioritise published data which would have been 
subject to peer review, but we will conduct sensitivity anal-
ysis to examine the impact of this decision.
When a study reports participant drop- out, we will note 
whether effect sizes were computed from the reduced 
sample (ie, per protocol) or the entire sample (ie, inten-
tion to treat, eg, using last observation carried forward) 
and prioritise intention to treat. When data are missing or 
ambiguously presented, we will contact study authors up 
to three times over 6 weeks for clarification.
Study characteristics and treatment network
We will provide a descriptive table summarising the key 
characteristics of each eligible study including interven-
tions used, patient populations and trial characteristics. 
A network diagram will show which interventions were 
compared, with larger network nodes indicating a greater 
number of patients and thicker connecting lines between 
nodes indicating a greater number of trials.
Network meta-analysis
Relative treatment effects across the whole network 
will be estimated with NMA. This method makes use of 
a wide pool of evidence by aggregating data from both 
direct head- to- head trials and indirect evidence (where 
two treatments can be compared indirectly via a common 
comparator such as placebo). The results of each treat-
ment comparison will be provided in a tabular form, 
which will present results based on NMA estimates and 
those from head- to- head trials only. The effectiveness 
of each treatment relative to a control reference will be 
presented in a forest plot. Mean ranks with their 95% 
credible intervals and a simple transformation of the 
mean rank will be used to provide a hierarchy of the best 
treatments.
If combined intervention data are available, we will use 
CNMA to estimate the relative effects of different treat-
ment components. CNMA14 can estimate the effects of 
individual treatment components based on single compo-
nent interventions (eg, exercise only) and combined 
interventions (eg, exercise+education) after disaggre-
gation of the individual intervention components, and 
thus can provide greater statistical power than NMA with 
conventional parametrisation. Similarly, individual treat-
ment component effects can be added to provide a more 
robust estimate of combined treatment effects compared 
with relying on direct combination studies only, and 
combinations can be modelled as additive or interac-
tive (synergistic or antagonistic) effects.29 This may be 
of particular benefit for OA intervention research given 
that combination treatments can be a particularly effec-
tive way for older adults to manage their greater adverse 
safety profile from pharmacological agents30 and that 
empirical data on combination treatments are relatively 
sparse.15
Estimation will be based on a random- effects model 
using the netmeta package in R,31 with any additional 
analysis that cannot be performed in netmeta carried out 
in an alternative package (eg, mvmeta in Stata 15.0).
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Transitivity and inconsistency in NMA
A fundamental assumption of NMA in general is that 
studies of different treatment comparisons should be 
similar in effect modifiers (participant and study char-
acteristics that modify the relative efficacy of the treat-
ments). To help assess this assumption, we will create and 
visually inspect a table summary of the distribution of 
potential effect modifiers (eg, baseline pain severity, OA 
severity, age, gender) across different treatment compar-
isons. We will also compare direct and indirect estimates 
for consistency, both globally across the whole network 
using a design by treatment interaction approach32 and 
locally for each comparison using the ‘back- calculation’ 
method.33 Using the latter method, we will highlight 
any substantive difference between direct and indirect 
estimates and advise caution in the interpretation of the 
corresponding NMA estimates.
We will proceed with NMA in the case of minor dissim-
ilarities, and if there are sufficient data, we will explore 
the influence of effect modifiers on inconsistency using 
network meta- regression. In the event of considerable 
dissimilarity, we will consider excluding network nodes 
or not proceeding with NMA if substantive inconsistency 
across nodes is still present.
If there is evidence of sequestration of pharmacolog-
ical and non- pharmacological treatments, such that there 
are no or very limited head- to- head pharmacological 
versus non- pharmacological comparisons, we will split 
the network and conduct separate analyses on pharma-
cological and non- pharmacological treatment networks 
separately and we will assume a common heterogeneity 
variance τ2 for each network. If splitting the network is 
not required, we will use one common heterogeneity 
variance for each of medication interventions vs control, 
non- pharmaceutical interventions vs control and medica-
tion vs non- pharmaceutical comparisons if data suggests 
τ2 is notably different for these three networks.34 35
Additivity assumption in CNMA
An assumption of CNMA is that summing individual 
treatment component effects to estimate the effect of 
a combined treatment reliably reflects the effect of this 
combination administered in practice.29 To help deter-
mine the plausibility of this assumption, we will check for 
consistency between effects estimated for combination 
interventions based on the additive model with those 
from any direct combination studies.36 We will also carry 
out a test of additivity,29 based on a comparison of treat-
ment estimates from the standard NMA model and the 
additive CNMA model. We will use clinical judgement to 
assess whether it is plausible that the components involved 
in a treatment combination are likely to operate through 
different pathways36 and, therefore, whether considering 
effects to be additive is appropriate. We will also compare 
the fit of additive and interaction models with the Devi-
ance Information Criteria statistic, and favour the addi-
tive model unless the interaction model is a significantly 
better fit. If any of these checks suggests intractable 
problems, we will conduct only a standard NMA where 
combination treatments are entered as distinct nodes 
in the network rather than estimating these based on a 
CNMA model.
Meta-regression and sensitivity analysis
If there are sufficient data, we will conduct network meta- 
regression to identify possible sources of notable hetero-
geneity adding the effect modifiers listed previously. We 
will also use meta- regression to examine whether relative 
treatment effects are moderated by the following: diag-
nostic method (clinical/radiographic), dosage (above 
or below the median dosage) and industry sponsorship 
(yes/no).
We will also assess the robustness of the findings to 
various decisions by performing sensitivity analyses 
removing studies with high risk of bias (RoB), samples 
with secondary OA and where scale conversions have 
been performed.
Publication bias
We will visually examine contour enhanced treatment- 
control comparison adjusted funnel plots when 10 or 
more studies are available, and further explore small study 
effects with Egger’s test for continuous outcomes and 
Peters’ test for binary outcomes.37 38 If bias is suspected we 
will explore this by including sample size as a covariate.
Evidence grading
The quality of the study evidence for the primary outcome 
of pain will be evaluated using the Confidence in Network 
Meta- Analysis (CINeMA) and presented in a Summary of 
Findings table. This approach was developed by Salanti 
et al39 and recently refined by Papakonstantinou et al.40 
CINeMA is based on the traditional GRADE (Grading 
of Recommendations, Assessment, Development and 
Evaluations) framework adapted for NMA, and provides 
a single overall confidence rating (‘high’, ‘moderate’, 
‘low’, ‘very low’) for each pairwise comparison based on 
the six domains: (1) within- study bias, (2) reporting bias, 
(3) indirectness, (4) imprecision, (5) heterogeneity and 
(6) incoherence. The overall confidence rating for each 
comparison is based on individual study ratings applying 
weights that mimic the study’s contribution to the treat-
ment effect size.
Within- study bias will be assessed with the revised 
Cochrane RoB 2.0 tool for RCTs,41 which rates potential 
for study bias arising from the randomisation process, 
deviations from the intended intervention, missing 
outcome data, measurement of outcomes and selective 
reporting. RoB and evidence appraisal will be conducted 
independently by two reviewers, with any disagreement 
resolved by discussion or arbitration by a third reviewer if 
required. We will present network plots40 to illustrate the 
level of bias in each comparison.
Patient and public involvement
This study is a synthesis of secondary data and will not 
require patient or public involvement.
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Ethics and dissemination
This study does not require ethical approval. We will 
disseminate our findings by publishing results in a peer- 
reviewed journal.
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Supplementary File 1 
 
PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to 
address in a systematic review protocol*  
Section and topic Item No                       Checklist item                                                                                                                        Page 
ADMINISTRATIVE INFORMATION 
Title:   
 Identification 1a Identify the report as a protocol of a systematic review                                                                                              1 
 Update 1b If the protocol is for an update of a previous systematic review, identify as such                                                      NA 
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number                                 2, 6 
Authors:   
 Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of 
corresponding author                                                                                                                                                    1 
 Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review                                                  18 
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; 
otherwise, state plan for documenting important protocol amendments                                                                      NA 
Support:   
 Sources 5a Indicate sources of financial or other support for the review                                                                                        18 
 Sponsor 5b Provide name for the review funder and/or sponsor                                                                                                      18 
 Role of sponsor or funder 5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol                                 18 
INTRODUCTION 
Rationale 6 Describe the rationale for the review in the context of what is already known                                                             5-6 
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, 
comparators, and outcomes (PICO)                                                                                                                                6 
METHODS 
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years 
considered, language, publication status) to be used as criteria for eligibility for the review                                        6-9 
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other 
grey literature sources) with planned dates of coverage                                                                                                  11 
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be 
repeated                                                                                                                                                                              
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Supp. File 1 
Study records:   
 Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review                                  12 
 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the 
review (that is, screening, eligibility and inclusion in meta-analysis)                                                                              12 
 Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any 
processes for obtaining and confirming data from investigators                                                                                      12-13 
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data 
assumptions and simplifications                                                                                                                                        12-13 
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with 
rationale                                                                                                                                                                              8-9 
Risk of bias in individual studies 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the 
outcome or study level, or both; state how this information will be used in data synthesis                                              17-18 
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised                                                                     15-16                    
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and 
methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall’s τ).   13,16 
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)                         16-19 
15d If quantitative synthesis is not appropriate, describe the type of summary planned                                                          n/a 
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)           17 
 Confidence in cumulative 
evidence 
17 Describe how the strength of the body of evidence will be assessed (such as GRADE)                                                   17-18  
* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important 
clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the 
PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.  
 
From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and 
meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647. 
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PRISMA NMA Checklist of Items to Include When Reporting A Systematic Review Involving 




Checklist Item Reported 
on Page # 
TITLE    
Title 1 Identify the report as a systematic review incorporating a 
network meta-analysis (or related form of meta-analysis).  
1 
    
ABSTRACT    
Structured 
summary  
2 Provide a structured summary including, as applicable:  
Background: main objectives 
Methods: data sources; study eligibility criteria, 
participants, and interventions; study appraisal; and 
synthesis methods, such as network meta-analysis.  
Results: number of studies and participants identified; 
summary estimates with corresponding confidence/credible 
intervals; treatment rankings may also be discussed. 
Authors may choose to summarize pairwise comparisons 
against a chosen treatment included in their analyses for 
brevity. 
Discussion/Conclusions: limitations; conclusions and 
implications of findings. 
Other: primary source of funding; systematic review 
registration number with registry name. 
2 
    
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what is 
already known, including mention of why a network meta-
analysis has been conducted.  
5 
Objectives  4 Provide an explicit statement of questions being addressed, 
with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
5-6 
    
METHODS    
Protocol and 
registration  
5 Indicate whether a review protocol exists and if and where it 
can be accessed (e.g., Web address); and, if available, 
provide registration information, including registration 
number.  
6 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale. Clearly describe eligible treatments 
included in the treatment network, and note whether any 
have been clustered or merged into the same node (with 
justification).  
6-9 
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Information 
sources  
7 Describe all information sources (e.g., databases with dates 
of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
11 
Search  8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 




10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
12-13 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
12-13 
Geometry of the 
network 
S1 Describe methods used to explore the geometry of the 
treatment network under study and potential biases related to 
it. This should include how the evidence base has been 
graphically summarized for presentation, and what 
characteristics were compiled and used to describe the 
evidence base to readers. 
13 
Risk of bias within 
individual studies  
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this 
was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
17-18 
Summary measures  13 State the principal summary measures (e.g., risk ratio, 
difference in means). Also describe the use of additional 
summary measures assessed, such as treatment rankings and 
surface under the cumulative ranking curve (SUCRA) values, 
as well as modified approaches used to present summary 
findings from meta-analyses. 
10, 13 
Planned methods of 
analysis 
14 Describe the methods of handling data and combining results 
of studies for each network meta-analysis. This should 
include, but not be limited to:   
• Handling of multi-arm trials; 
• Selection of variance structure; 
• Selection of prior distributions in Bayesian analyses; 
and 




S2 Describe the statistical methods used to evaluate the 
agreement of direct and indirect evidence in the treatment 
network(s) studied. Describe efforts taken to address its 
presence when found. 
14-15 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
17-18 
Additional analyses  16 Describe methods of additional analyses if done, indicating 
which were pre-specified. This may include, but not be 
limited to, the following:  
• Sensitivity or subgroup analyses; 
• Meta-regression analyses;  
• Alternative formulations of the treatment network; 
and 
13-16 
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• Use of alternative prior distributions for Bayesian 






   
RESULTS†    
Study selection  17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 




S3 Provide a network graph of the included studies to enable 




S4 Provide a brief overview of characteristics of the treatment 
network. This may include commentary on the abundance of 
trials and randomized patients for the different interventions 
and pairwise comparisons in the network, gaps of evidence in 





18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
NA 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment.  
NA 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for 
each study: 1) simple summary data for each intervention 
group, and 2) effect estimates and confidence intervals. 
Modified approaches may be needed to deal with information 
from larger networks. 
 NA 
Synthesis of results  21 Present results of each meta-analysis done, including 
confidence/credible intervals. In larger networks, authors 
may focus on comparisons versus a particular comparator 
(e.g. placebo or standard care), with full findings presented 
in an appendix. League tables and forest plots may be 
considered to summarize pairwise comparisons. If additional 
summary measures were explored (such as treatment 




S5 Describe results from investigations of inconsistency. This 
may include such information as measures of model fit to 
compare consistency and inconsistency models, P values 
from statistical tests, or summary of inconsistency estimates 
from different parts of the treatment network. 
NA 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across 




23 Give results of additional analyses, if done (e.g., sensitivity 
or subgroup analyses, meta-regression analyses, alternative 
network geometries studied, alternative choice of prior 
distributions for Bayesian analyses, and so forth).  
NA 
    
DISCUSSION    
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Summary of 
evidence  
24 Summarize the main findings, including the strength of 
evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy-
makers).  
NA 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of 
bias), and at review level (e.g., incomplete retrieval of 
identified research, reporting bias). Comment on the validity 
of the assumptions, such as transitivity and consistency. 
Comment on any concerns regarding network geometry (e.g., 
avoidance of certain comparisons). 
NA 
Conclusions  26 Provide a general interpretation of the results in the context 
of other evidence, and implications for future research.  
NA 
    
FUNDING    
Funding  27 Describe sources of funding for the systematic review and 
other support (e.g., supply of data); role of funders for the 
systematic review. This should also include information 
regarding whether funding has been received from 
manufacturers of treatments in the network and/or whether 
some of the authors are content experts with professional 




PICOS = population, intervention, comparators, outcomes, study design. 
* Text in italics indicateS wording specific to reporting of network meta-analyses that has been added to 
guidance from the PRISMA statement. 
† Authors may wish to plan for use of appendices to present all relevant information in full detail for 
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Supplementary File 3 
 
Medline (OVID) search string 
1 Randomized controlled trial.pt. 
2 Controlled clinical trial.pt. 
3 randomi?ed.ab. 
4 placebo.ab. 





10 exp animals/ not humans.sh. 
11 9 not 10 
12 exp osteoarthritis/ 
13 (osteoarthriti* or osteo-arthriti* or degenerative joint disease or arthroses or arthrosis or 
osteoarthros* or coxarthrosis).tw. 
14 (degenerative adj2 arthritis).tw. 
15 (knee adj4 OA).tw. 
16 or/12-15 
17 exp pain management/ 
18 exp mind-body therapies/ 
19 exp exercise/ 
20 exp exercise therapy/ 
21 exp sports/ 
22 ((strength$ or isometric$ or isotonic$ or isokinetic$ or aerobic$ or endurance or  weight$) 
adj2 (exercis$ or train$)).ti,ab. 
23 (resistance training or weight training or physiotherapy or mind?body or tai?ji or tai?chi or 
taiji or yoga or mind?body or exercise or sport or running or jogging or treadmill or swimming 
or walking  or  cycling or rowing or physical activity or physical conditioning or aquarobics or 
pilates or physical fitness).ti,ab. 
24 or/18-23 
25 exp patient education as topic/ 
26 exp *health education/ 
27 self care/ or (self?care or self?help or self?manage*).ti,ab. 
28 ((health or patient$) adj2 (educat$ or information)).tw. 
29 or/25-28 
30 exp Transcutaneous Electric Nerve Stimulation/ 
31 Transcutaneous adj4 Stimulation or TENS 
32 (electric$ adj (nerve or  therapy)).tw. 
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33 Electromagnetic Fields/ 
34 electromagnetic$.ti,ab. 
35 exp Electric Stimulation Therapy/ 
36 (electric$ adj3 stimulat$).tw. 
37 (alternat$ adj3 electric$).tw. 
38 exp ultrasonography/ 
39 exp Ultrasonic Therapy/ 
40 us.fs. 
41 (ultrasound$ or ultrasonic$).tw. 
42 short wave therapy.tw. 
43 ultrasonograph$.tw. 
44 heat/tu 
45 (heat or hot or ice).tw. 
46 cryotherapy.sh,tw. 
47 (vapocoolant or phonophoresis).tw. 
48 exp hyperthermia, induced/ 
49 (hypertherm$ or thermotherapy).tw. 
50 (fluidotherapy or compression).tw. 
51 or/30-50 
52 24 or 29 or 51 
53 exp analgesics/ 
54 exp acetaminophen/ 
55 (acetaminophen or acamol or acephen or acetaco or acetamidophenol or 
acetaminophen or acetominophen or algotropyl or anacin 3 or anacin-3 or anacin3 or datril or 
hydroxyacetanilide or "n-(4-hydroxyphenyl)acetanilide" or n-acetyl-p-aminophenol or panadol 
or paracetamol or tylenol or p-acetamidophenol or p-hydroxyacetanilide).ti,ab. 
56 or/53-55 
57 exp Anti-Inflammatory Agents, Non-Steroidal/ 
58 aspirin.mp. or exp Aspirin/ 
59 etodolac.mp. or exp Etodolac/ 
60 diclofenac.mp. or exp Diclofenac/ 
61 sulindac.mp. or exp Sulindac/ 
62 (indometacin or indomethacin).mp. or exp Indomethacin/ 
63 piroxicam.mp. or exp Piroxicam/ 
64 fenoprofen.mp. or exp Fenoprofen/ 
65 flurbiprofen.mp. or exp Flurbiprofen/ 
66 ibuprofen.mp. or exp Ibuprofen/ 
67 ketoprofen.mp. or exp Ketoprofen/ 
68 naproxen.mp. or exp Naproxen/ 
69 diflunisal.mp. or exp Diflunisal/ 
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70 metamizol.mp. or exp Dipyrone/ 
71 phenylbutazone.mp. or exp Phenylbutazone/ 
72 phenazone.mp. or exp Antipyrine/ 
73 exp cyclooxygenase inhibitors/ or exp cyclooxygenase 2 inhibitors/ 
74 exp Meclofenamic Acid/ 
75 tolmetin.mp. or exp Tolmetin/ 
76 (nsaids or non?steroidal anti?inflammat$ or acetylsalicyl$ or carbasalate calcium or 
aceclofenac or alclofenac or meloxicam or dexibuprofen or dexketoprofen or tiapro$ or 
propyphenazone or celecoxib or etoricoxib or nabumeton or parecoxib or ((cyclooxygenase or 
cyclo-oxygenase) adj3 inhibitor*) or rofecoxib or valdecoxib or lumiracoxib or vioxx or 
celebrex or bextra or prexige or arcoxia or floctafenine or meclofenamate or oxaprozin or 
tenoxicam).mp. 
77 or/57-76 
78 (bufexamac OR bufexine OR calmaderm OR ekzemase OR diclofenac OR solaraze OR 
pennsaid OR voltarol OR emugel OR voltarene OR voltarol OR optha OR voltaren OR 
etofenamate OR afrolate OR algesalona OR bayro OR deiron OR etofen OR flexium OR 
flogoprofen OR rheuma-gel OR rheumon OR traumalix OR traumon OR zenavan OR felbinac 
OR dolinac OR flexfree OR napageln OR target OR traxam OR fentiazac OR domureuma OR 
fentiazaco OR norvedan OR riscalon OR fepradinol OR dalgen OR flexidol OR cocresol OR 
rangozona OR reuflodol OR pinazone OR zepelin OR flufenamic OR dignodolin OR rheuma 
OR lindofluid OR sastridex OR lunoxaprofen OR priaxim OR flubiprofen OR fenomel OR 
ocufen OR ocuflur OR tulip OR ibuprofen OR cuprofen OR "deep relief" OR fenbid OR 
ibu?cream OR ibugel OR ibuleve OR ibumousse OR ibuspray OR "nurofen gel" OR proflex 
OR motrin OR advil OR radian OR ralgex OR ibutop OR indomethacin OR indocin OR 
indospray OR isonixin OR nixyn OR ketoprofen OR tiloket OR oruvail OR powergel OR 
solpaflex OR ketorolac OR acular OR trometamol OR meclofenamic OR naproxen OR 
naprosyn OR niflumic OR actol OR flunir OR niflactol topico OR niflugel OR nifluril OR 
oxyphenbutazone OR californit OR diflamil OR otone OR tanderil OR piketoprofen OR 
calmatel OR triparsean OR piroxicam OR feldene OR pranoprofen OR oftalar OR pranox OR 
suxibuzone OR danilon OR flamilon OR ufenamate OR fenazol OR flector OR 
benzydamine).mp. 
79 or/77-78 
80 exp Administration, Topical/ or (topical* OR cutaneous OR dermal OR transcutaneous 
OR transdermal OR percutaneous OR skin OR massage OR embrocation OR gel OR 
ointment OR aerosol OR cream OR creme OR lotion OR mouse OR foam OR liniment OR 
spray OR rub OR balm OR salve OR emulsion OR oil OR patch OR plaster).mp. 
81 79 AND 80 
82 capsaicin.mp. AND 80 
83 exp analgesics, opioid/ or (alfentanil or alphaprodine or buprenorphine or butorphanol or 
codeine or dextromoramide or dextropropoxyphene or dihydromorphine or diphenoxylate or 
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ethylketocyclazocine or ethylmorphine or etorphine or fentanyl or hydrocodone or 
hydromorphone or levorphanol or meperidine or meptazinol or methadone or methadyl 
acetate or morphine or nalbuphine or opiate alkaloids or opium or oxycodone or 
oxymorphone or pentazocine or phenazocine or phenoperidine or pirinitramide or promedol or 
remifentanil or sufentanil or tapentadol or tilidine or tramadol).mp. 
84 (cymbalta or duloxetine).mp. 
85 exp hyaluronic acid/ or viscosupplement/ or viscosupplementation/ or (hyaluronic or 
hyaluronate* or hyaluronan*).mp. 
86 (adant or arthrease or arthrum h or artz or artzal or biohy or durolane or etapharm or 
euflexxa or fermathron or go-on or healon or healonid or hyalflex or hyalgan or hyalurons or 
hylan* or hylartil or hylectin or hyruan or nasha or neovisc or nrd-101 or nuflexxa or orthovisc 
or ostenil or polireumin or polyreumin or replasyn or slm-10 or supartz or suplasyn or suvenyl 
or synject or synocrom or synvisc).mp. 
87 or/85-86 
88 *Adrenal Cortex Hormones/ or *17-Hydroxycorticosteroids/ or *11-
Hydroxycorticosteroids/ or *Hydroxycorticosteroids/ or *Ketosteroids/ or *17-Ketosteroids/ or 
*Androstenedione/ or *Prednisolone/ or *Glucocorticoids/ or *Triamcinolone Acetonide/ or 
*Hydrocortisone/ or *cortisone/ 
89 (adrenal cortex hormone* or adrenal cortical hormone* or adrenal steroid* or 
adrenocortical hormone* or adrenocortical steroid* or adrenocorticalsteroid* or 
adrenocorticosteroid* or cortical steroid* or cortico-steroid* or corticoid* or corticosteroid* or 
dermocortico-steroid* or dermocorticosteroid* or glucocortic* or hydroxycorticosteroid* or 
ketosteroid* or androstenedion* or steroid or triamcinolone hexacetonide or hydrocortison* or 
prednisolone or Prednison* or cortison* or Pregnadiene*).mp. 
90 or/88-89 
91 (intraartic* or intra-artic* or inject* or infiltration* or infiltrating).mp. 
92 and/90,91 
93 56 or 77 or 81 or 82 or 83 or 84 or 87 or 87 or 92 
94 17 or 52 or 93 
95 11 AND 16 AND 94  
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